Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Only one more day until #WorldPsoriasisDay! We look forward to uniting with @PsoriasisIFPA on October 29 to shine a light on psoriasis. #UnitedNowAct
— UCB News (@ucb_news) 28.10.2021 -
Great recognition for our sustainability and French teams who won the "Raison d'Etre Européenne" (European Sense of Purpose) from the "Why Project" https://t.co/1k9x8jg5Z4 https://t.co/DtzEizGdxb
— UCB News (@ucb_news) 27.10.2021 -
At UCB, we’re dedicated to fostering a supportive and diverse company culture to give us a greater appreciation of each individual reality and create a meaningful difference in the lives of patients. Learn about our jobs at UCB: https://t.co/wkfuD3uIAa
— UCB News (@ucb_news) 26.10.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
